One-Year Evaluation of Paliperidone Palmitate 6-Monthly: Satisfaction and Perceived Effectiveness Among Patients, Relatives, and Clinicians
Patient Preference and Adherence · 2025-05 · Volume 19 · 1573-1582
DOI: 10.2147/ppa.s517038 ↗Kurz gefasst
Fachartikel in der Zeitschrift Patient Preference and Adherence, 2025-05. Verfasst von Sofía Manchado Perero und 24 weiteren Autor:innen. Beteiligte Einrichtung: Fundación Jiménez Díaz University Hospital, Madrid, Spain. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Background
Patient satisfaction and perceived treatment effectiveness play a critical role in healthcare outcomes and overall well-being. Understanding patient experiences can help identify barriers to adherence and guide improvements in therapy. Previous studies, such as those conducted with PP3M and PP1M, have highlighted the importance of patient satisfaction in optimizing the management of chronic conditions, demonstrating that satisfaction is linked to better adherence and overall treatment success. Nonetheless, there was no data available with patients treated with paliperidone 6-month (PP6M). Therefore, we aimed to evaluate the perspectives, including the perceived effectiveness and satisfaction of patients, their relatives and mental health professionals on the twice-yearly treatment with PP6M in usual clinical practice.
Methods
The cohort of patients derived from the P2Y study. This is a multicenter, prospective study across different sites in Europe. Patients, relatives and psychiatrists were asked for satisfaction, by using the Medication Satisfaction Questionnaire (MSQ), and perceived effectiveness. We included all patients who were initiated or switched to PP6M and completed one year of treatment.
Results
A total of 233 patients were included in this study, of which 9 (4%) discontinued PP6M at 12 months. Most patients were male (69%, 160 participants), 66% (156 patients) carried a diagnosis of schizophrenia and 16% (38 patients) of comorbid substance use disorder. Furthermore, 22% (51 patients), 70% (164 patients) and 8% (19 patients) were treated with PP1M, PP3M and other oral/LAIs antipsychotics, respectively. The majority of patients (81.5%, n = 190/233), relatives/carers (81.1%, n = 189/233) and clinicians (90.9%, n = 212/233) were extremely satisfied, very satisfied or satisfied 1 year after switching from PP1M, PP3M and other antipsychotic to PP6M with similar findings between patients diagnosed with schizophrenia and other diagnoses. Last, 42% of patients, 45% of their relatives and 40% of clinicians perceived PP6M as more effective compared to the previous treatment. In contrast, only 3% of patients, relatives and clinicians perceived PP6M as less effective.
Conclusion
Patients, their carers and relatives as well as mental health professionals reported a high satisfaction rate with PP6M, and equally good or even better perceived effectiveness compared to PP1M, PP3M or other oral or LAIs antipsychotics in the majority of cases. Improved patient experience with PP6M could improve treatment continuity and reduce hospitalization rates.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Fundación Jiménez Díaz University Hospital, Madrid, Spain.
- Department of Psychiatry, Santa Lucía University Hospital, Cartagena, Murcia, Spain.
- Centre of Mental Health Molina de Segura, Molina de Segura, Murcia, Spain.
- Department of Psychiatry, Marqués de Valdecilla University Hospital, Universidad de Cantabria, Santander, Spain.
- Psychiatry and Mental Health Research Group, Instituto Investigación Sanitaria Valdecilla (IDIVAL), Santander, Spain.
- Centre of Mental Health Lorca, Lorca, Murcia, Spain.
ORCID-Profile: Alba García-Pérez, Guillermo Isidro García, Sergio Sánchez-Alonso, Sofia Pappa, Juan Antonio García-Carmona
Zitieren
APA
Manchado Perero, S., Rodríguez Lorente, A., García-Pérez, A., Isidro García, G., Forcen-Muñoz, L. A., Ovejero, S., Sáez Povedano, R., González-Galdámez, A. L., Iturralde, L. M., Bonilla, M. R., Fuentes-Pérez, P., Ovejas-Catalán, C., Suárez-Pinilla, P., Fernandez Abascal Puente, B., Omaña Colmenares, M., Campos-Navarro, M. P., Baca-García, E., Fernández, A. L., Benavente-López, S., …, & García-Carmona, J. A. (2025). One-Year Evaluation of Paliperidone Palmitate 6-Monthly: Satisfaction and Perceived Effectiveness Among Patients, Relatives, and Clinicians. Patient Preference and Adherence, Volume 19, 1573-1582. https://doi.org/10.2147/ppa.s517038
Vancouver
Manchado Perero S, Rodríguez Lorente A, García-Pérez A, Isidro García G, Forcen-Muñoz LA, Ovejero S, et al. One-Year Evaluation of Paliperidone Palmitate 6-Monthly: Satisfaction and Perceived Effectiveness Among Patients, Relatives, and Clinicians. Patient Preference and Adherence. 2025;Volume 19:1573-1582. doi:10.2147/ppa.s517038
BibTeX
@article{ManchadoPerero2025,
author = {Manchado Perero, Sofía and Rodríguez Lorente, Ana and García-Pérez, Alba and Isidro García, Guillermo and Forcen-Muñoz, Luis Alberto and Ovejero, Santiago and Sáez Povedano, Rocío and González-Galdámez, Ana Luisa and Iturralde, Laura Mata and Bonilla, Mariluz Ramirez and Fuentes-Pérez, Paloma and Ovejas-Catalán, Claudia and Suárez-Pinilla, Paula and Fernandez Abascal Puente, Blanca and Omaña Colmenares, Miguel and Campos-Navarro, María Pilar and Baca-García, Enrique and Fernández, Ana Lara and Benavente-López, Sergio and Platero, Alberto Raya and Navalón, Miguel Barberán and Sánchez-Alonso, Sergio and Vázquez-Bourgon, Javier and Pappa, Sofia and García-Carmona, Juan Antonio},
title = {One-Year Evaluation of Paliperidone Palmitate 6-Monthly: Satisfaction and Perceived Effectiveness Among Patients, Relatives, and Clinicians},
journal = {Patient Preference and Adherence},
year = {2025},
volume = {Volume 19},
pages = {1573--1582},
doi = {10.2147/ppa.s517038}
}
EUVIMED